Inova Translational Medicine Institute and GNS Healthcare Partner To Advance Diagnosis and Prevention of Preterm Birth

FALLS CHURCH, Va. and CAMBRIDGE, Mass., Aug. 8, 2013 -- /PRNewswire/ -- The Inova Translational Medicine Institute (ITMI) at Inova Fairfax Hospital and GNS Healthcare today announced a partnership to develop and commercialize computer models capable of predicting risk of preterm live birth, built using next generation sequencing and electronic medical record data. GNS and ITMI will license the models and corresponding software to academic researchers, health systems, and pharmaceutical/biotechnology companies, paving the way for potentially more effective diagnosis and the reduction in risk of preterm birth.

(Logo:  http://photos.prnewswire.com/prnh/20121112/NE10632LOGO )

In the United States, 12 percent of babies are born at less than 37 weeks gestation, which causes nearly 10,000 deaths[1] and costs the health system approximately $28 billion per year. The causes of preterm birth are complex and in about half of cases, are unknown. While there is understood to be a genetic component, no individual genes have been identified as causative, to date.

"We are very excited to partner with the Inova Translational Medicine Institute," said Colin Hill, CEO and co-founder of GNS Healthcare. "Using ITMI's unprecedentedly rich and multimodal preterm birth genomic data set, we will build models that can document the complex interactions underlying preterm birth. These models will create new ways for clinicians and scientists to understand these interactions and will accelerate the discovery of new diagnostic tools and treatments for this condition, as well as other complex conditions."

The partnership will result in the commercial availability of the preterm birth predictive models and corresponding software, including optional access to the underlying ITMI data. The models will be built from ITMI's massive database, which includes both normal birth and preterm birth family cohorts, using GNS's data analytics platform, REFS™ (Reverse Engineering and Forward Simulation), and will link genetic and molecular factors with clinical data and health outcomes. The ITMI database includes whole genome sequencing (SNP, CNV, SV), RNAseq expression, CpG methylation, proteomic, metabolomic, imaging, EMR, clinical phenotypes, and patient survey data for over 2400 individuals. These models will characterize the complex relationships among many variables in order to identify the associations and underlying causal mechanisms of preterm birth and will allow for personalized prediction of preterm birth risk and gestational length. This, in turn, will help prioritize the testing of potential new diagnostic and treatment plans for at-risk patients.

"We have 826 families in our preterm birth study with 285 babies born at less than 37 weeks of gestation. Partnering with our colleagues at GNS provides the best opportunity to build a risk assessment/predictive model that takes into account the many variables, including genomic, clinical, environmental and behavioral factors, that combine to cause a preterm delivery," said John Niederhuber, EVP of Inova Health System and CEO of ITMI.

Joe Vockley, COO and CSO of ITMI added, "ITMI is excited to enter into this research agreement with GNS Healthcare. We see this work in preterm birth as a first step toward building similar prediction models for other complex genomic diseases, such as autism, diabetes and obesity, supported by ITMI's massive familial whole genome sequence databases. Prediction followed by prevention is a key component of translational medicine."

About GNS Healthcare GNS Healthcare is a big data analytics company that has developed a scalable approach for the discovery of what works in healthcare, and for whom. Our analytics solutions are being applied across the healthcare industry: from pharmaceutical and biotechnology companies, health plans and hospitals, to integrated delivery systems, pharmacy benefits managers, and accountable care organizations. REFS™ is GNS Healthcare's scalable, supercomputer-enabled framework for discovering new knowledge directly from data. REFS™ automates the discovery and extraction of causal network models from observational and experimental data and uses high-throughput simulations to generate new knowledge.

About Inova Translational Medical Institute The Inova Translational Medicine Institute (ITMI) is a not-for-profit research institute delving into the genomics component of personalized medicine. ITMI is utilizing genomic and clinical information from patients to develop innovative methods for personalized patient care. Pilot studies at the Institute have generated a large genomic and clinical data set that can be used as pilot data in a variety of fields, from computational biology to psychology as well as more obvious biomedical research applications. ITMI's goal is to utilize information from its pilot studies to better understand and predict the onset of disease, leading to the implementation of preventive medicine based on the unique genomics of the individual patient.

About Inova Inova is a not-for-profit health care system located in the Washington, D.C. metropolitan area, serving over two million people with over 1,700 licensed beds based in Northern Virginia.  Inova consists of five hospitals including the area's only Level 1 Trauma Center and Level 3 Neonatal Intensive Care unit.  Inova encompasses many health services including the nationally and internationally recognized Inova Heart and Vascular Institute (IHVI), Inova Translational Medicine Institute (ITMI) on genomics, Inova Neuroscience Institute and Inova Children's Hospital.  Inova's mission is to improve the health of the diverse community it serves through excellence in patient care, education and research.  More information and statistics about Inova available at www.inova.org.

[1] Gallagan et al. (2006) The Contribution of Preterm Birth to Infant Mortality Rates in the United States. Pediatrics 118(4): 1566-1573.

Contact: Inova Tony Raker Public Relations Officer 703-645-2736

GNS Healthcare Tom Neyarapally EVP, Corporate Development 617-374-2300

SOURCE GNS Healthcare


Read more here: http://www.sacbee.com/2013/08/08/5633397/inova-translational-medicine-institute.html#storylink=cpy

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.